Associated Papers
A Common UDP-Glucuronosyltransferase (UGT)1A Haplotype Is Associated With Accelerated Aging in Humanized Transgenic Mice.
Langhans B et al.
Oxidative Medicine and Cellular Longevity, 2025
Novel NARS2 variants in a patient with early-onset status epilepticus: case study and literature review.
Yang N et al.
Bmc Pediatrics, 2024
Evolutionary history of adenomas to colorectal cancer in FAP families.
Yang C et al.
Frontiers in Genetics, 2024
Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies on irinotecan glucuronidation.
Tagawa K et al.
Toxicology Mechanisms and Methods, 2023
The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients.
Lee CK et al.
Genomics & Informatics, 2022
Functional Interaction between Cytochrome P450 and UDP-Glucuronosyltransferase on the Endoplasmic Reticulum Membrane: One of Post-translational Factors Which Possibly Contributes to Their Inter-Individual Differences.
Miyauchi Y et al.
Biological & Pharmaceutical Bulletin, 2021
UDP-glucuronosyltransferase polymorphisms affect diethylnitrosamine-induced carcinogenesis in humanized transgenic mice.
Landerer S et al.
Cancer Science, 2020
UGT1A3 and Sex Are Major Determinants of Telmisartan Pharmacokinetics-A Comprehensive Pharmacogenomic Study.
Hirvensalo P et al.
Clinical Pharmacology and Therapeutics, 2020
The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics.
Chan HT et al.
Oncology and Therapy, 2019
Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
Cecchin E et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2018
Renal oncocytoma characterized by the defective complex I of the respiratory chain boosts the synthesis of the ROS scavenger glutathione.
Kürschner G et al.
Oncotarget, 2017
Clinical presentations and molecular studies of invasive renal epithelioid angiomyolipoma.
Chuang CK et al.
International Urology and Nephrology, 2017
Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray.
Tsunedomi R et al.
Cancer Science, 2017
Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
Liu D et al.
Bmc Cancer, 2017
Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: a case report with pharmacogenetic analysis to personalize treatment.
Del Re M et al.
The Epma Journal, 2017
Prevalence of UDP-glucuronosyltransferase polymorphisms (UGT1A6∗2, 1A7∗12, 1A8∗3, 1A9∗3, 2B7∗2, and 2B15∗2) in a Saudi population.
Alkharfy KM et al.
Saudi Pharmaceutical Journal : Spj : the Official Publication of the Saudi Pharmaceutical Society, 2017
Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
Raaijmakers MI et al.
Oncotarget, 2016
UGT1A1*6, UGT1A7*3 and UGT1A9*1b polymorphisms are predictive markers for severe toxicity in patients with metastatic gastrointestinal cancer treated with irinotecan-based regimens.
Cui C et al.
Oncology Letters, 2016
Genetic polymorphisms of human UDP-glucuronosyltransferase (UGT) genes and cancer risk.
Hu DG et al.
Drug Metabolism Reviews, 2016
Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients.
Xie XC et al.
Acta Pharmacologica Sinica, 2015
The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data.
Tang X et al.
Nucleic Acids Research, 2014
A steroid metabolizing gene variant in a polyfactorial model improves risk prediction in a high incidence breast cancer population.
Jupe ER et al.
Bba Clinical, 2014
Differences in UGT1A1, UGT1A7, and UGT1A9 polymorphisms between Uzbek and Japanese populations.
Maeda H et al.
Molecular Diagnosis & Therapy, 2014
The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: haplotype associations and gene–environment interactions.
Angstadt AY et al.
Genes, Chromosomes & Cancer, 2014
Alteration of the function of the UDP-glucuronosyltransferase 1A subfamily by cytochrome P450 3A4: different susceptibility for UGT isoforms and UGT1A1/7 variants.
Ishii Y et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2014
Contribution of environment and genetics to pancreatic cancer susceptibility.
Hocevar BA et al.
Plos One, 2014
Polymorphisms of uridine glucuronosyltransferase gene and irinotecan toxicity: low dose does not protect from toxicity.
Tziotou M et al.
Ecancermedicalscience, 2014
Differences in frequencies of UGT1A9, 1A7, and 1A1 genetic polymorphisms in Chinese Tibetan versus Han Chinese populations.
Yan W et al.
Genetics and Molecular Research : Gmr, 2013
UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
Hazama S et al.
Cancer Science, 2013
S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis.
Kim SY et al.
British Journal of Cancer, 2013
Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.
Lévesque E et al.
The Journal of Pharmacology and Experimental Therapeutics, 2013
The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent.
Stringer F et al.
European Journal of Clinical Pharmacology, 2013
Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.
Inoue K et al.
The Tohoku Journal of Experimental Medicine, 2013
Pharmacogenetic study of deferasirox, an iron chelating agent.
Lee JW et al.
Plos One, 2013
Exome sequencing resolves apparent incidental findings and reveals further complexity of SH3TC2 variant alleles causing Charcot-Marie-Tooth neuropathy.
Lupski JR et al.
Genome Medicine, 2013
Is there diversity among UGT1A1 polymorphism in Japan?
Kobayashi M et al.
World Journal of Gastrointestinal Oncology, 2012
Gilbert syndrome redefined: a complex genetic haplotype influences the regulation of glucuronidation.
Ehmer U et al.
Hepatology (baltimore, Md.), 2012
High enzyme activity UGT1A1 or low activity UGT1A8 and UGT2B4 genotypes increase esophageal cancer risk.
Dura P et al.
International Journal of Oncology, 2012
Genetic variants in carcinogen-metabolizing enzymes, cigarette smoking and pancreatic cancer risk.
Jang JH et al.
Carcinogenesis, 2012
Polymorphisms in heterocyclic aromatic amines metabolism-related genes are associated with colorectal adenoma risk.
Eichholzer M et al.
International Journal of Molecular Epidemiology and Genetics, 2012
Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer.
Wong NS et al.
Pharmacogenetics and Genomics, 2011
Interactions among genetic variants in tobacco metabolizing genes and smoking are associated with head and neck cancer susceptibility in North Indians.
Sharma R et al.
Dna and Cell Biology, 2011
Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.
Sai K et al.
Expert Opinion on Drug Metabolism & Toxicology, 2011
Evaluation of the association studies of single nucleotide polymorphisms and hepatocellular carcinoma: a systematic review.
Jin F et al.
Journal of Cancer Research and Clinical Oncology, 2011
Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations.
Horsfall LJ et al.
Annals of Human Genetics, 2011
Genetic polymorphisms of genes involved in DNA repair and metabolism influence micronucleus frequencies in human peripheral blood lymphocytes.
Dhillon VS et al.
Mutagenesis, 2011
Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.
Deenen MJ et al.
The Oncologist, 2011